货号:A242112
同义名:
Atavaquone; BW 566C
Atovaquone is a medication used to treat or prevent for pneumocystis pneumonia, toxoplasmosis, malaria, and babesia.
规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
描述 | Atovaquone is a powerful suppressor of protozoan parasites with a broad-spectrum activity, but an extremely low water solubility and bioavailability. Oral administration of atovaquone nanoemulsion increased oral bioavailability, tissue distribution and mice survival time and reduced parasitemia and number and size of the brain cysts[3]. While atovaquone has potent in vitro activity against Toxoplasma gondii, it is poorly absorbed after oral administration and shows poor therapeutic efficacy against TE(toxoplasma encephalitis). Development of TE and mortality in mice treated with 1.0- or 0.1-mg/kg i.v. doses of ANS (atovaquone nanosuspensions) did not differ from that in mice treated orally with 100 mg of atovaquone/kg[4]. Atovaquone, an antiprotozoal and antipneumocystic agent, is predominantly cleared by biliary excretion of unchanged parent drug[5]. Atovaquone potently inhibits the propagation of MCF7-derived CSCs, with an IC-50 of 1 μM, as measured using the mammosphere assay. In addition to targeting the proliferation of CSCs (Cancer Stem-like Cells), atovaquone also induces apoptosis in both CD44+/CD24low/- CSC and ALDH+ CSC populations, during exposure to anchorage-independent conditions for 12 hours[6]. |
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
NCT03163121 | Malaria | Phase 1 | Recruiting | October 2018 | Netherlands ... 展开 >> Leiden University Medical Center, Albinusdreef 2 Recruiting Leiden, Netherlands, 2333 ZA Contact: Leo G. Visser, MD 31715266354 l.g.visser@lumc.nl Contact: Meta Roestenberg, MD, PhD 31715264400 M.Roestenberg@lumc.nl Principal Investigator: Leo G. Visser, MD Radboud University Medical Center, Geert Grooteplein 28 Recruiting Nijmegen, Netherlands, 6525 GA Contact: Robert W. Sauerwein, MD 31243610577 Robert.Sauerwein@radboudumc.nl Contact: Jona Walk, MD 31243613663 Jona.Walk@radboudumc.nl Principal Investigator: Robert W. Sauerwein, MD 收起 << |
NCT01218893 | Plasmodium Falciparum Malaria | Not Applicable | Completed | - | Netherlands ... 展开 >> Leiden University Medical Centre Leiden, Netherlands, 2300 RC 收起 << |
NCT01236612 | Plasmodium Falciparum Malaria | Not Applicable | Completed | - | Netherlands ... 展开 >> Radboud University Nijmegen Medical Centre Nijmegen, Netherlands, 6500 HB 收起 << |
计算器 | ||||
存储液制备 | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
2.73mL 0.55mL 0.27mL |
13.63mL 2.73mL 1.36mL |
27.26mL 5.45mL 2.73mL |
CAS号 | 95233-18-4 |
分子式 | C22H19ClO3 |
分子量 | 366.84 |
SMILES Code | O=C1C([C@H]2CC[C@H](C3=CC=C(Cl)C=C3)CC2)=C(O)C(C4=C1C=CC=C4)=O |
MDL No. | MFCD00889188 |
别名 | Atavaquone; BW 566C; Wellvone; Mepron; hydroxynaphthoquinone 566C80; GlaxoSmithKline brand of atovaquone; Glaxo Wellcome brand of atovaquone; compound 566; atovaquone GlaxoSmithKline brand; 566C80 hydroxynaphthoquinone; 566C80; 566C; BW 556C-80 |
运输 | 蓝冰 |
InChI Key | BSJMWHQBCZFXBR-UHFFFAOYSA-N |
Pubchem ID | 74989 |
存储条件 |
In solvent -20°C:3-6个月-80°C:12个月 Pure form Sealed in dry, store in freezer, under -20°C |
动物实验配方 |
5% DMSO+corn oil 0.5 mg/mL |